^
    8d
    Long-term Outcomes of Second Allogeneic Transplantation following CD7 CAR-T in Remission for T-cell Acute Lymphoblastic Leukemia or Lymphoma. (PubMed, Transplant Cell Ther)
    NS7CAR-T therapy showed a high CR rate for T-ALL/LBL patients who relapsed post-transplant. Consolidation with a second transplant appears feasible and may offer a promising therapeutic strategy for these heavily pretreated patients. However, the high NRM demonstrated the need for further efforts to mitigate this risk. Patients who did not receive consolidative transplantation experienced uniformly poor outcomes.
    Journal
    |
    CD7 (CD7 Molecule)
    |
    SENL101
    7ms
    Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P2 trial
    |
    SENL101
    8ms
    Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL). (PubMed, Br J Haematol)
    We compared infection rates and immune cell subsets in 60 R/R T-ALL/LBL patients receiving naturally selected CD7 CAR-T (NS7CAR-T) with 60 R/R B-ALL patients undergoing CD19 CAR-T...This study indicates that while CD7 CAR-T therapy significantly reduces CD7(+) T cells, it does not lead to increased short-term infection rates. The notable expansion of non-CAR-T-derived CD7(-) T and NK cells helps preserve immune function, highlighting distinct therapeutic mechanisms between CD7 CAR-T and CD19 CAR-T due to their different lineage restrictions.
    Journal
    |
    CD7 (CD7 Molecule)
    |
    SENL101
    over1year
    Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia. (PubMed, Blood)
    This trial underscores the potential promising treatment of dVHH NS7CAR-T in providing clinical benefits with a manageable safety profile to CD7-positive AML patients, warranting further investigation. NCT04938115.
    Journal
    |
    CD7 (CD7 Molecule)
    |
    SENL101
    almost2years
    Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia (clinicaltrials.gov)
    P=N/A, N=50, Completed, Hebei Senlang Biotechnology Inc., Ltd. | Recruiting --> Completed | Trial completion date: Jun 2023 --> Oct 2023
    Trial completion • Trial completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide • SENL101
    over2years
    Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma (ASH 2023)
    SENL101 expanded robustly but persisted shortly, which on the other hand, contributed to the recovery of CD7 + T and NK cells, thereby reducing the risk of infection. An expanded cohort is warranted to verify the long-term benefit of SENL101 for T-cell malignant patients.
    P1 data
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    CD8 positive
    |
    SENL101
    over2years
    CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study (clinicaltrials.gov)
    P1, N=9, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P1 trial
    |
    SENL101
    3years
    Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Hebei Senlang Biotechnology Inc., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10) • CD7 (CD7 Molecule)
    |
    CD7 expression
    |
    SENL101
    over3years
    Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 expression
    |
    SENL101
    4years
    SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies (clinicaltrials.gov)
    P1, N=18, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P1 trial
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD7 (CD7 Molecule)
    |
    SENL101
    4years
    Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial. (PubMed, Blood)
    More patients and longer follow-up are needed for validation. Clinical Trial can be found at NCT04572308, https://clinicaltrials.gov/.
    P1 data • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD7 (CD7 Molecule)
    |
    SENL101
    over4years
    First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL) (ASH 2021)
    Prior to the CAR-T cells infusion, patients received systemic bridging chemotherapy due to rapid disease progression and then all patients received intravenous fludarabine (30mg/m 2 /d) and cyclophosphamide (300mg/m 2 /d) (FC) lymphodepleting chemotherapy for 3 consecutive days (Day -5 to Day -3)...Conclusion This study demonstrated that CD7-targeted CAR-T therapy offers an opportunity to achieve CR for CD7-positive MPAL patients even for those who relapsed post-transplant. Safety was manageable, however, more data on additional patients and longer observation times are needed to further evaluate the efficacy of CD7 CAR-T products.
    Clinical • P1 data • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD7 (CD7 Molecule)
    |
    FLT3 mutation
    |
    cyclophosphamide • fludarabine IV • SENL101